-
Mashup Score: 1
BACKGROUND: While initial data for transcatheter aortic valve replacement (TAVR) in aortic stenosis patients with mitral stenosis (MS) suggested a poor short-term prognosis, outcomes for contemporary balloon-expandable valves remain unknown. The aim of this retrospective multicenter registry study was to compare the potential impact of MS on TAVR outcomes with balloon-expandable valves. METHODS: Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry and Centers for Medicare & Medicaid Services claims data were used to obtain a cohort of 327 925 patients who underwent TAVR with current balloon-expandable valves (SAPIEN 3, SAPIEN 3 Ultra, or SAPIEN 3 Ultra Resilia) between June 2015 and December 2022 across 791 sites. Severe MS (defined as >10 mm Hg mean gradient or <1.5 cm2 area) was compared with mild or less MS (defined as 2 cm2 area) using propensity matching to minimize confounding variables. RESULTS: Patients w
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 12Circulation: Cardiovascular Interventions | AHA/ASA Journals - 7 day(s) ago
Learn the benefits of becoming an AHA/ASA Professional Member and
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet-
With @CRFheart #TCT2023 fast approaching @CircIntv is looking for the next exciting advancement in IC for simultaneous publication. It’s time to take that study and put it into manuscript format. Submit to https://t.co/WQQWlESj3g @TCTconference #AHAJournals #cardiotwitter https://t.co/t5NSsfgN8q
-
-
Mashup Score: 5AHA24 - 9 day(s) ago
Download the mobile program today to easily access event session s, speakers, exhibitors, and organizer messages. Use the native app to personalize your schedule, take notes, share contacts, and more. Build your schedule directly on your computer. Then, install the native app and sync your schedule to your mobile
Source: eppro01.ativ.meCategories: General Medicine News, CardiologistsTweet-
Join @CircIntv editors @SVRaoMD & @JDawnAbbott1 at #AHA24. Circulation: CV Interventions 2023-2024 Editors' Picks: The Best and What's Next Sun, Nov 17 @ 8-9:15am Moderators: Jinnette D Abbott, Sunil V Rao Room: S103D https://t.co/nCL8YNUiLs
-
-
Mashup Score: 19
BACKGROUND: The clinical impact of a chronic total occlusion (CTO) in patients with 3-vessel coronary artery disease undergoing fractional flow reserve–guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents or coronary artery bypass grafting (CABG) is unclear. METHODS: The FAME 3 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 3) compared fractional flow reserve–guided PCI with CABG in patients with 3-vessel coronary artery disease. The primary end point was major adverse cardiac and cerebrovascular events, a composite of death, myocardial infarction, stroke, or repeat revascularization at 1 year. In this substudy, the 3-year outcomes were analyzed in patients with or without a CTO. RESULTS: Of the patients randomized to PCI or CABG in the FAME 3 trial, 305 (21%) had a CTO. In the PCI arm, revascularization of the CTO was attempted in 61% with a procedural success rate of 88%. The incidence of major adverse cardiac and c
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
How does the presence of a CTO effect outcomes in FFR guided therapy for 3-vessel CAD? A comparison of PCI versus CABG. A FAME-3 Substudy @HisaoOtsuki @T_Takahashi_MD @wfearonmd #cardiotwitter #AHAJournals https://t.co/g9tRM9tWSi https://t.co/AOZJe8o5sa
-
-
Mashup Score: 5AHA24 - 10 day(s) ago
Download the mobile program today to easily access event session s, speakers, exhibitors, and organizer messages. Use the native app to personalize your schedule, take notes, share contacts, and more. Build your schedule directly on your computer. Then, install the native app and sync your schedule to your mobile
Source: eppro01.ativ.meCategories: General Medicine News, CardiologistsTweet-
Join @CircIntv editors @SVRaoMD & @JDawnAbbott1 at #AHA24. Circulation: CV Interventions 2023-2024 Editors' Picks: The Best and What's Next Sun, Nov 17 @ 8-9:15am Moderators: Jinnette D Abbott, Sunil V Rao Room: S103D https://t.co/nCL8YNUiLs
-
-
Mashup Score: 1
BACKGROUND: Mitral annular calcification with valve dysfunction remains a challenging syndrome. Operative risk is high, and available transcatheter therapies are limited. METHODS: This study describes our initial experience with a novel procedure to address large mitral annuli when no surgical or trial-based transcatheter mitral valve replacement device is available. The rationale was to shorten the intercommissural distance using commissural mitral transcatheter edge-to-edge repair (TEER) followed by valve-in-mitral annular calcification transcatheter mitral valve replacement with a balloon-expandable aortic valve platform. Patients with long intercommissural distances and large mitral annulus areas were selected based on a high perceived risk of transcatheter valve embolization. Patients underwent mitral TEER with MitraClip in a commissural position, followed immediately by transseptal transcatheter mitral valve replacement with a 29 mm SAPIEN 3 valve. RESULTS: Thirteen patients were
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Annular Reduction by Cinching with TEER in the Commissure (ARCTIC) TMVR. A hybrid mitral valve procedure for large mitral annuli @jamiemccabeMD @davidelison1 @gb_mackensen @richardsheuMD @loganlvincent #cardiotwitter #AHAJournals https://t.co/l9PYJxeYOR https://t.co/Mo3K8TFo3D
-
-
Mashup Score: 5
BACKGROUND: Covered stent correction (CSC) of a superior sinus venosus atrial septal defect is an alternative to surgery in selected patients, but anatomic variation means that assessment for CSC requires a 3-dimensional anatomic understanding. Heart VR is a virtual reality (VR) system that rapidly displays and renders multimodality imaging without prior image segmentation. The aim of this study was to evaluate the performance of the Heart VR system to assess patient suitability for CSC. METHODS: In a blinded fashion, 2 interventionalists reviewed preprocedural computed tomography scans using Heart VR to assess the feasibility of CSC, including the potential need for pulmonary vein protection. The total review time using VR was recorded. RESULTS: Using conventional imaging, 15 patients were deemed suitable for CSC, but at catheterization, 3 cases were unsuitable. Using VR, when both interventionalists agreed that a case was suitable for CSC (n=12), all proved technically feasible. In t
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Virtual reality for planning covered stent correction of Sinus Venosus ASD @nastephenson21 @k_pushparajah @jmsimpsonmd #cardiotwitter #AHAJournals https://t.co/vu64GensHn https://t.co/lTRDIkGZjp
-
-
Mashup Score: 23
Background: The Valve Academic Research Consortium for High Bleeding Risk (VARC-HBR) has recently introduced a consensus document that outlines risk factors to identify high bleeding risk (HBR) in patients undergoing transcatheter aortic valve replacement (TAVR). The objective of the present study was to evaluate the prevalence and predictive value of the VARC-HBR definition in a contemporary, large-scale TAVR population. Methods: Multicenter study including 10,449 patients undergoing TAVR. Based on consensus, twenty-one clinical and laboratory criteria were identified and classified as major or minor. Patients were stratified as at low, moderate, high, and very high bleeding risk according to VARC-HBR definition. The primary endpoint was the rate of BARC type 3 or 5 bleeding at 1 year, defined as the composite of peri-procedural (within 30 days) or late (after 30 days) bleeding. Results: Patients with at least one VARC-HBR criterion (n=9,267, 88.7%) had a higher risk of BARC 3 or 5 bl
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Defining bleeding risk in TAVR patients. Validation of the Valve Academic Research Consortium High Bleeding Risk Definition published simultaneously @crfheart #TCT2024 https://t.co/eaWNvdSoYE @MAvvedimento @pedro_cepas @IUCPQ #AHAJournals #Cardiotwitter https://t.co/cQaI8r4Dh3
-
-
Mashup Score: 9
Background: Percutaneous microaxial ventricular assist devices (pVAD) have the potential to reduce mortality of patients with cardiogenic shock (CS). However, the association between the distribution of pVAD-performing centers and outcomes of CS has not been explored. Methods: This observational study included Medicare fee-for-service beneficiaries aged 65–99 years treated with pVAD for CS from 2016 to 2020 and examined the associations between patient outcomes and two exposure variables: hospitals’ procedure volumes of pVAD and patient-hospital distances (in quintiles [Qn]). We developed Cox proportional hazard regression for 180-day mortality and heart failure (HF) readmission rates and multivariable logistic regression for in-hospital outcomes, adjusting for patient demographics, comorbidities, concomitant treatments, and hospital characteristics, including CS volume, teaching status, and the ability to perform extracorporeal membrane oxygenation. Results: A total of 6,637 patients
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Understanding the balance between hospital volume and patient/hospital distance to outcomes in patients treated with percutaneous microaxial VAD for cardiogenic shock. https://t.co/PQUute20Ug Published simultaneously with @crfheart #TCT2024 #AHAJournals #cardiotwitter https://t.co/TPEaO1xPxx
-
-
Mashup Score: 8Three-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients | Circulation: Cardiovascular Interventions - 1 month(s) ago
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis, but data are limited on younger, low-risk patients. This analysis compares outcomes in low-surgical-risk patients aged <75 years receiving TAVR versus surgery. METHODS: The Evolut Low Risk Trial randomized 1414 low-risk patients to treatment with a supra-annular, self-expanding TAVR or surgery. We compared rates of all-cause mortality or disabling stroke, associated clinical outcomes, and bioprosthetic valve performance at 3 years between TAVR and surgery patients aged <75 years. RESULTS: In patients <75 years, 352 were randomized to TAVR and 351 to surgery. Mean age was 69.1±4.0 years (minimum 51 and maximum 74); Society of Thoracic Surgeons Predicted Risk of Mortality was 1.7±0.6%. At 3 years, all-cause mortality or disabling stroke for TAVR was 5.7% and 8.0% for surgery (P=0.241). Although there was no difference between TAVR and surgery in all-cause mortal
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
TAVR in low-risk younger patients at 3-years@RodrigoBagur @drnvanmieghem @MichaelMwachu @ChetcutiStan @nkleiman @arnaudsudre @RikAdrMD @Drmmumtaz #cardiotwitter #AHAJournals https://t.co/M68QqIWhT8 https://t.co/2Bik3uo7fv
-
What is the outcome for TAVR with balloon expandable valve in patients with severe mitral stenosis? A report from the TVT Registry @Anirudh_KumarMD @chetanhuded @GrantReedMD @sachingoelmd @docHJ @jamiemccabemd @MayraGuerreroMD @tavrkapadia #cardiotwitter https://t.co/Nc3yAHk8Oz https://t.co/kN8eRUvPgf